Last reviewed · How we verify
A Single - Blind, Randomized, - Controlled Clinical Trial With Inactivated Influenza Vaccine (Split Virion) (0.5ml Formulation)
The clinical trial was conducted in Jintan City of Jiangsu Province, China in May, 2006. The purpose of the clinical trial was to evaluate the safety and immunogenicity against Hualan's Influenza Vaccine (Split Virion), Inactivated (0.5ml) administered on age 6 months and old population.
Details
| Lead sponsor | Hualan Biological Engineering, Inc. |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 900 |
| Start date | 2006-05 |
| Completion | 2006-10 |
Conditions
- Influenza
Interventions
- Influenza split vaccine of 15 μg HA
- Influenza split vaccine of 15 μg HA
- Influenza split vaccine
Primary outcomes
- Number of participants with adverse events as a measure of safety study — 28 days after the vaccination
Include ADR, adverse event and severe adverse event.
Countries
China